As an anti-inflammatory, pleiotropic cytokine [60], IL-10 can contribute to cancer progression through several ways by binding to one of its two glycosylated receptors IL-10R1 on T cells, B cells, natural killer cells, mast cells, monocytes or DCs, to inhibit inflammation [61].or by binding to its alternative receptor IL-10R2 to inhibit production of pro-inflammatory cytokines [62]. Here, IL10 is linked to cancer.